Singapore Paincare appoints UOB Kay Hian as continuing sponsor, replacing Novus

• Singapore Paincare appointed UOB Kay Hian as continuing sponsor, replacing Novus Corporate Finance, effective July 30, 2026.
• Switch cited as driven by commercial reasons.
• Novus reported no known unflagged Catalist Rules non-compliance issues at the company at the time of the change.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Singapore Paincare Holdings Ltd. published the original content used to generate this news brief via Singapore Exchange Limited (SGX) (Ref. ID: WIN1KZDWWJNWOC9D) on July 28, 2026, and is solely responsible for the information contained therein.